Transparency notification – Gilead holds 25.10% of Galapagos shares
Mechelen, Belgium; 13 November 2019; 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc.
Mechelen, Belgium; 13 November 2019; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc.
Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 11 November 2019 from Gilead Sciences, Inc. (acting as a parent undertaking or a controlling person), who notified that Gilead Therapeutics A1 Unlimited Company, an indirect subsidiary of Gilead Sciences, Inc., holds 16,207,477 of Galapagos' voting rights, consisting of 16,207,477 shares, as a result of subscribing to a capital increase in the framework of the exercise of the Initial Warrant A and thus receiving 2,617,791 new Galapagos shares on 6 November 2019. This represents 25.10% of Galapagos' currently outstanding 64,571,622 shares. Gilead Therapeutics A1 Unlimited Company thus crossed above the 25% threshold of Galapagos' voting rights by acquisition of voting securities on 6 November 2019.
The notification specifies furthermore that (i) Gilead Therapeutics A1 Unlimited Company is a direct subsidiary of Gilead Biopharmaceutics Ireland UC, (ii) Gilead Biopharmaceutics Ireland UC is a direct subsidiary of Gilead Sciences, Inc., and (iii) Gilead Sciences, Inc. has no controlling shareholder.
The full transparency notification is available on the Galapagos website.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. The Company's pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Galapagos' ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
| Galapagos Contacts | |
| Investors: | Media: |
| Elizabeth Goodwin | Carmen Vroonen |
| VP Investor Relations | Senior Director Communications |
| +1 781 460 1784 | +32 473 824 874 |
| Sofie Van Gijsel | Evelyn Fox |
| Director Investor Relations | Director Communications |
| +32 485 19 14 15 | +31 6 53 591 999 |
| [email protected] | [email protected] |
1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Attachment
